We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

SEC Threatens Inspire With Civil Action

Law360 (October 23, 2006, 12:00 AM EDT) -- Inspire Pharmaceuticals Inc. disclosed Monday that it may face charges from the Securities and Exchange Commission over a Phase 3 clinical trial for its dry-eye product candidate, Prolacria.

The Durham, N.C.-based biopharmaceutical company said it received a Wells Notice last Thursday, which means the SEC has preliminarily decided to recommend an enforcement action.

However, the notice does give Inspire time to respond to the SEC in an attempt to resolve the matter, which resulted from a previously disclosed investigation. Inspire has said it and its officers...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.